Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

10x Genomics Q4 2023 Adj EPS $(0.24) Beats $(0.36) Estimate, Sales $183.98M Beat $182.80M Estimate

Author: Benzinga Newsdesk | February 15, 2024 05:11pm
10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.36) by 33.33 percent. The company reported quarterly sales of $183.98 million which beat the analyst consensus estimate of $182.80 million by 0.64 percent. This is a 17.76 percent increase over sales of $156.23 million the same period last year.

Posted In: TXG


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist